The Group’s patent portfolio contains eight technologies, and combinations of technologies, at various stages of patent protection. Primary intellectual property priority is dated back to March 2013 and all patents have now reached the PCT (Patent Cooperation Treaty) or International Stage of patent filing. The treaty covers intellectual property protection in almost all global states (currently 149 nations) the first two of which are now, published. The same two patents are now in the national phase awaiting approval in each nation state where filed.
All patents are registered to, and owned by MAP IP Holding Ltd part of the MAP Sciences Group.
The method and approach of MALDI ToF MS analysis on urine, culture fluid and blood are protected by these individual patents or combined IP, within these patents and owned by MAP IP Holding Ltd. Intellectual property and knowhow are granted, through an exclusive license, to MAP Technologies LLC for development and commercial exploitation for up to 25 years.